Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight

Over 200 companies are advancing more than 240 pipeline Alzheimer's disease therapies across various clinical development stages. The market is being driven by an aging population, rising disease prevalence, and the emergence of disease-modifying therapies that enable earlier intervention and biomarker-guided care. Two therapies have recently received FDA approval: KISUNLA (donanemab) from Eli Lilly and LEQEMBI (lecanemab-irmb) from Eisai/Biogen, both targeting amyloid plaques to slow disease progression.

10/22/2026, 1:00 PM • GlobeNewswire

Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility

Bristol Myers Squibb has demonstrated more stable and consistent revenue growth over the past two years, leading in seven of eight quarters. Novo Nordisk experienced significant volatility, with a dramatic 32% revenue spike in Q1 2026 following its Wegovy weight-loss pill launch, but faced sequential declines in Q2 2026 due to pricing pressure and ordering patterns. While Novo Nordisk's GLP-1 portfolio drives investor interest, its heavy dependence on Ozempic and Wegovy (70% of sales) presents concentration risk compared to Bristol Myers Squibb's more diversified growth portfolio.

10/22/2026, 7:10 AM • The Motley Fool

Vanguard Health Care ETF vs iShares U.S. Healthcare ETF

Vanguard Health Care ETF (VHT) and iShares U.S. Healthcare ETF (IYH) both provide U.S. healthcare sector exposure with identical 5-year returns, but VHT offers significantly better value with 411 holdings, a lower 0.09% expense ratio versus IYH's 0.37%, and a higher 1.4% dividend yield. While IYH takes a more concentrated approach with 100 stocks focused on large-cap healthcare companies, VHT is recommended for most investors seeking lower costs and broader diversification.

10/21/2026, 6:30 PM • The Motley Fool

Where Will Novo Stock Be in 10 Years?

Novo Nordisk, a Denmark-based pharmaceutical leader in diabetes and obesity markets, has faced recent setbacks but could bounce back over the next decade. The company's pipeline includes promising candidates like CagriSema, Amycretin, and UBT251 that could drive growth. However, patent expirations in 2032, increased competition, and regulatory uncertainties present significant challenges. Despite these risks, the analyst views Novo as an attractive long-term buy with potential for competitive returns, especially with dividend reinvestment.

10/21/2026, 3:28 PM • The Motley Fool

Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight

The global oral drugs market is experiencing steady growth driven by increasing chronic disease prevalence and patient preference for convenient treatment options. The market is projected to grow from USD 1 trillion in 2025 to USD 1.6 trillion by 2034 at a ~6% CAGR. North America leads with 36% market share, while Asia-Pacific is expected to register the fastest growth. Key drivers include advancements in drug delivery technologies, expansion of oral therapies across oncology and other therapeutic areas, and rising pharmaceutical R&D investments.

10/21/2026, 1:00 PM • GlobeNewswire

Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026

Moderna has surged over 600% in 2026, driven by breakthrough Phase 3 trial results for its personalized cancer vaccine (intismeran autogene) combined with Merck's Keytruda, plus FDA approval for its flu vaccine mFLUSIVA. However, despite strong innovation, the stock appears overvalued at a $90 billion market cap with a 45% downside according to Wall Street analysts. The company would need to generate unrealistic revenue levels to justify current valuations, leaving little room for error.

10/21/2026, 10:00 AM • The Motley Fool

Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock?

Novo Nordisk announced Phase 3 trial results for CagriSema, its next-generation obesity drug combining semaglutide and cagrilintide, showing 25% mean weight loss in women compared to 3% for placebo. While results are competitive with existing treatments like Eli Lilly's Zepbound (26% efficacy), they are not superior enough to significantly recapture market share from Eli Lilly's dominant position. The modest investor reaction suggests the drug alone may not materially improve Novo Nordisk's fortunes, though the company's broader pipeline in other therapeutic areas remains a potential catalyst.

10/21/2026, 7:45 AM • The Motley Fool

Here's What I'm Planning With My Eli Lilly Position

An investment analyst discusses their strategy with Eli Lilly stock, highlighting the pharmaceutical industry's business growth and robust pipeline of new treatments. The article emphasizes the diversification benefits of pharmaceutical stocks due to their lower correlation with the broader economy.

10/20/2026, 11:26 PM • The Motley Fool

Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight

The global migraine market is projected to grow at a 6% CAGR through 2036, reaching expansion driven by rising prevalence, improved diagnosis rates, and development of novel therapies beyond CGRP inhibitors. Key emerging treatments include PACAP-targeted therapies, TRPA1 antagonists, and next-generation neuromuscular approaches. The market was valued at USD 8.3 billion in 2025 across seven major markets, with the United States leading.

10/19/2026, 1:00 PM • GlobeNewswire

Is Eli Lilly Stock a Buy Right Now?

Eli Lilly is expanding access to its products at lower realized prices while improving margins—an unusual combination that could strengthen further as manufacturing costs decline. The company's retatrutide drug approaches a potential 2027 filing, and investors are evaluating whether the current valuation still offers room for growth.

10/19/2026, 11:45 AM • The Motley Fool

Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market

Regeneron Pharmaceuticals is emerging as a competitive player in the rapidly growing weight loss market with two differentiated candidates: olatorepatide, which shows better gastrointestinal tolerability than competitors with 19% mean weight loss, and trevogrumab, designed to preserve lean muscle mass alongside anti-obesity drugs. Beyond weight loss, Regeneron's strong pipeline including Dupixent and newer Eylea HD formulation positions it for medium-term growth.

10/19/2026, 10:24 AM • The Motley Fool

Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It

Warren Buffett warns that investors are in an excessive gambling mood, engaging in risky short-term options trading rather than long-term investing. Despite market volatility concerns, pharmaceutical and biotech stocks like Vertex Pharmaceuticals, Eli Lilly, and AbbVie are positioned to weather economic downturns due to consistent demand for their treatments.

10/19/2026, 4:10 AM • The Motley Fool

Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.

Viking Therapeutics raised $575 million through a stock offering and convertible notes to fund multiple phase 3 trials for its obesity drug VK2735 and pipeline development. The company expects to have cash through at least 2028, with key trial results expected between 2027-2028. The company's future depends on VK2735's clinical success.

10/18/2026, 6:30 PM • The Motley Fool

Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy.

Ken Griffin's Citadel significantly increased positions in healthcare stocks during Q2, boosting AbbVie by 546%, Abbott Laboratories by 349%, and Eli Lilly by 291%. The moves suggest Griffin is seeking defensive, dividend-yielding stocks amid anticipated market volatility. AbbVie, a Dividend King with 54 consecutive years of dividend increases, is highlighted as a strong buy with attractive valuation and solid earnings growth.

10/18/2026, 8:15 AM • The Motley Fool

Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher

Eli Lilly's pipeline extends beyond its blockbuster weight-loss drug Zepbound, with three promising medicines poised to drive future growth: Foundayo (oral GLP-1 for weight loss), Onswik (once-weekly basal insulin for diabetes), and retatrutide (investigational triple-hormone weight-loss drug showing 28.3% average weight loss). These drugs target different patient segments and indications, positioning Eli Lilly to maintain market leadership despite increasing competition.

10/16/2026, 2:38 PM • The Motley Fool